Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) Shares Outstanding (Diluted Average) (2021 - 2025)

Historic Shares Outstanding (Diluted Average) for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Q3 2025 value amounting to $56.1 million.

  • 4D Molecular Therapeutics' Shares Outstanding (Diluted Average) rose 102.94% to $56.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.1 million, marking a year-over-year increase of 102.94%. This contributed to the annual value of $53.9 million for FY2024, which is 3785.75% up from last year.
  • Per 4D Molecular Therapeutics' latest filing, its Shares Outstanding (Diluted Average) stood at $56.1 million for Q3 2025, which was up 102.94% from $55.9 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' Shares Outstanding (Diluted Average)'s 5-year high stood at $56.1 million during Q3 2025, with a 5-year trough of $26.7 million in Q2 2021.
  • For the 5-year period, 4D Molecular Therapeutics' Shares Outstanding (Diluted Average) averaged around $41.4 million, with its median value being $38.7 million (2023).
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first skyrocketed by 5057.05% in 2024, then soared by 102.94% in 2025.
  • Quarter analysis of 5 years shows 4D Molecular Therapeutics' Shares Outstanding (Diluted Average) stood at $27.7 million in 2021, then rose by 16.66% to $32.4 million in 2022, then grew by 20.95% to $39.1 million in 2023, then surged by 37.86% to $53.9 million in 2024, then rose by 4.05% to $56.1 million in 2025.
  • Its last three reported values are $56.1 million in Q3 2025, $55.9 million for Q2 2025, and $55.7 million during Q1 2025.